Press Releases
Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jul. 13, 2022– Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in PLOS ONE show that the company’s Percepta Genomic Sequencing Classifier (GSC) is highly accurate in…
Read More
New synthetic controls add to growing portfolio of NGS applications for viral diseases Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today launched two human monkeypox virus synthetic DNA controls1. Positive controls provide quality…
Read More
Quantitative biomarkers of demyelination can improve clinical trial design and accelerate development of disease-modifying therapeutics Excerpt from the Press Release: SAN FRANCISCO, July 14, 2022 /PRNewswire/ — Rune Labs, a precision neurology software and data platform company, today announced it is enrolling patients with multiple sclerosis (MS) in a study to identify neurophysiological biomarkers of the disease. The…
Read More
In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo received a median number of 10 injections over the two years versus 15 injections for those treated with aflibercept, potentially decreasing the…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older who…
Read More
Excerpt from the Press Release: FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress in the Phase II Part II clinical study of the Company’s ADHD medicine (ABV-1505). Since results on the…
Read More
Represents First Ever Epigenomic Controller, a New Class of Programmable mRNA Therapeutics, to Receive IND Clearance Phase 1/2 Clinical Trial Expected to Launch in 2H’22 and Will Evaluate the Safety and Preliminary Antitumor Activity of OTX-2002 Excerpt from the Press Release: CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), today announced that it has received…
Read More
Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults Excerpt from the Press Release: CAMBRIDGE, MA / ACCESSWIRE / July 14, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Health Canada has approved the use of…
Read More
CAMBRIDGE, Mass.–(BUSINESS WIRE)–LG Chem recently announced the enrollment of first subject in Phase 1 clinical trial of LG203003, LG Chem’s second NASH (non-alcoholic steatohepatitis) drug in development. Excerpt from the Press Release: LG203003 received clearance from the U.S. Food and Drug Administration (FDA) in March 2022 for the Company’s Investigational New Drug (IND) application to…
Read More
Clinical trial collaboration supports global registrational Phase 3 study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib Agreement is supportive of the planned initiation of ZILO-301 in Q3 2022 and will also supply ibrutinib for the open-label companion study ZILO-302 Excerpt from the Press Release: SAN DIEGO, July 14, 2022…
Read More